FDA clears Adherium’s usage tracker for AstraZeneca inhaler

Patients may view their medication usage data on the Smartinhaler app. (Adherium)

Australian smart inhaler maker Adherium has scored an FDA nod for its SmartTouch device, for use with AstraZeneca’s Symbicort aerosol inhalers.

Designed to improve medication adherence, the SmartTouch device attaches to a patient’s inhaler and tracks the date and time that it is used. It then transmits this data to an app on a smartphone or tablet. Physicians can look at a patient’s usage trends to tailor his or her treatment plan.

“The SmartTouch for Symbicort is the most advanced Smartinhaler product to date for Adherium and a key product in our strategic collaboration with AstraZeneca by bringing the benefits of digital monitoring to patients and their physicians,” said Adherium CEO Arik Anderson, in a statement.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

The FDA clearance is Adherium’s third. Its Smartinhaler offerings include devices and apps that help patients manage respiratory disease.

RELATED: Health, environmental tracker could head off asthma attacks without drugs

The device can be used in home monitoring programs—such as those geared at preventing hospital readmission—where drug adherence after hospital discharge is an important goal, Adherium said in the statement.

In 2015, the companies announced a nonexclusive agreement under which Adherium would supply AstraZeneca with smart inhalers for use with any combination of budesonide and formoterol, the active ingredients in the Symbicort product. The next month, AstraZeneca backed Adherium in its IPO.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.